Oct 28, 2026 earnings call — NGS growth and MRD reimbursement progress
Raised 2026 revenue guidance to $807 million to $809 million after Q3 total revenue of $209 million.
Revenue $0.2B (est $0.2B) · EPS $0.07 (est $0.06) · Next-quarter revenue outlook $0.8B–$0.8B
Key quotes
"In the quarter, NGS grew 29% and volumes grew 17%, with large panel volumes growing above 25%."
"In August, RaDaR ST received MolDX coverage for immunotherapy treatment response monitoring, our third Medicare-covered indication and a cornerstone of our MRD launch."
"We remain on track to transition our heme NGS portfolio, the largest revenue component of our NGS business, to the NovaSeq X platform in the first half of 2027."
Analyst Q&A 11
CEO transition and succession timing
Q (David Westenberg · Piper Sandler): Analyst asked why leadership change was made now, what Warren's role has been, how he will communicate long-term ambition, and lessons from the prior transition.
A: Management said the move came from deliberate succession planning and that Warren earned the role after leading commercial and lab operations. They said the change gives continuity with Tony moving to Executive Chair and allows Warren to own the upcoming budget; they plan an Investor Day in first half of 2027 to share longer-term ambition.
"So continuity in the strategy is critically important, and maintaining continuity within the leadership is important as well." — Warren Stone (COO)
AUP growth and durability
Q (Puneet Souda · Leerink): Analyst asked how to think about AUP growth and whether the recent AUP levels will sustain into 2027. Also asked whether NGS volume growth is new customers or share gains.
A: Management said AUP grew 11% this quarter and they had guided high single-digit AUP for the year; they expect AUP to normalize to mid-single digits in a normal environment. On NGS volume, management said growth includes both new customer acquisition and increased volume from existing customers aided by bidirectional interfaces.
"So AUP growth came in at 11% for the current quarter as we reported in our numbers this quarter." — Abhishek Jain (CFO)
Drivers of NGS growth
Q (William Bonello · Craig-Hallum): Analyst wanted the relative importance of sales force expansion, specialized teams, and new products to NGS growth, and when the low-margin customer exit will annualize.
A: Management said growth is multi-factor: product launches contribute materially (five 2023 products now about 25% of revenue), sales force expansion is showing good returns, and customer experience work helps. They said the high-volume, low-value customer peaked in Q3 2025 and its effect should mute into Q4 and normalize through 2027, with non-oncology volumes growing mid-single digits.
"If we go back to the 5 products that we launched in 2023, that is contributing about 25% of revenue today, and the actual growth of those 5 products was north of that -- well north of that 25%." — Warren Stone (COO)
RaDaR ST ordering and reimbursement
Q (Mark Massaro · BTIG): Analyst asked why clinicians order RaDaR ST in indications without reimbursement and whether this is to build interest before reimbursement; also asked about commercial payer wins for PanTracer Liquid and RaDaR ST.
A: Management said they are promoting RaDaR ST broadly and IO coverage allows broader market positioning, which helps adoption and workflow embedding. They confirmed recent payer wins have been primarily for PanTracer Liquid and RaDaR but declined to give more detail on which plans.
"When we initially had the good opportunity to reenter the market, we basically had head, neck, and a subset of breast." — Anthony Zook (CEO)
Pharma business and focus areas
Q (Matthew Larew · William Blair): Analyst asked whether the nonclinical/pharma segment remains attractive long-term and how it fits with core growth drivers.
A: Management said the company will prioritize molecular growth drivers (NGS, MRD, whole genome) while viewing pharma work as a potential enabler of those drivers. They said they will avoid low-value bespoke solutions and instead focus pharma activities on higher-tech work that supports clinical growth and margins.
"Our focus long-term has to be on what our growth drivers are, and our growth drivers are molecular, right?" — Anthony Zook (CEO)
PanTracer Pro impact on tissue and liquid orders
Q (Mason Carrico · Stephens): Analyst asked whether PanTracer Liquid adoption boosts tissue orders and for quantification of any halo effect.
A: Management said PanTracer Pro gives optionality: when tissue is insufficient they can reflex to liquid, and the portfolio approach increases uptake. They added they often see tissue first and reflex to liquid when needed, and isolated cases where customers use liquid first are addressed by promoting tissue adoption.
"We actually see -- it's more the -- we see more the other way around." — Warren Stone (COO)
Margins and Lab of the Future effects
Q (Tycho Peterson · Jefferies): Analyst asked about gross margin ceiling, Lab of the Future benefits, and whether margin gains are tied to one-time payer improvements.
A: Management said adjusted gross margin improved driven by AUP growth (NGS mix), RCM gains, and lab sourcing efficiencies; NovaSeq X benefits will show in second half of 2027 and more in 2028. They noted MRD volumes without reimbursement are a short-term gross margin headwind and pharma/legacy segments may be slightly down but not material to 2027 guidance.
"On the adjusted gross margin, again, Tycho, we are seeing a solid growth there of 300 basis point increase year-over-year." — Abhishek Jain (CFO)
Competition with large CLIA labs
Q (Daniel Brennan · TD Cowen): Analyst asked how often Neo runs into large CLIA labs, overlap of customers, competitive win rates, and trends.
A: Management said large CLIA labs are present in many accounts but Neo wins based on portfolio strength, diagnosis-through-therapy positioning, and workflow simplification; they have daily couriers and a seat at the table from heme work. They do not provide specific win-rate data.
"A lot of our business is certainly take away from a number of those players based on our portfolio opportunity, from diagnosis and therapy selection, not MRD." — Warren Stone (COO)
NGS mix: large versus targeted panels
Q (Subhalaxmi Nambi · Guggenheim): Analyst asked current share of large (comprehensive) versus targeted NGS panels by volume, expected mix trend, and remaining AUP runway; also asked about contract renegotiation uplifts and RaDaR attachment targets.
A: Management said volume is approaching roughly 50/50 between large and targeted panels, with large panels growing faster (north of 25%) which supports higher AUPs. They said RaDaR attach rate is about 30% and sits in the midpoint of their internal goal, with opportunities to increase attachment over time; they did not recall the '300 contracts' remark and did not give detail on contract uplifts.
"We are quickly approaching sort of a 50/50 mark now between large and targeted panels from a volume perspective." — Warren Stone (COO)
MRD investment and oncology data monetization
Q (Lu Li · BofA): Analyst asked how large MRD investment will be, what areas will get funding, and how the oncology data asset will be monetized.
A: Management said they will increase disciplined investments in sales force (not a doubling), R&D (raising R&D spend from ~4%-5% toward 7%), and Lab of the Future while offsetting with G&A efficiencies. They said their genomics data set will grow with WGS plans in 2028+, is high-margin and double-digit growing, and they plan to continue investing in it.
"So it would be a really disciplined expansion on the sales force side, that we'll be happy to share when we get into the February session." — Anthony Zook (CEO)
Indica Labs partnership and AI pathology plans
Q (Joseph Conway · Needham): Analyst asked whether the Indica Labs partnership will develop clinical AI pathology tools or remain research-focused.
A: Management said the partnership began in 2016 and enabled their image database; they expect AI-driven image interpretation to drive operational efficiency and capacity gains and plan to develop AI algorithms that will be tested to support diagnosis and therapy selection, with both operational and commercial value.
"One is operation efficiency, and it's all AI-driven at the end of the day, where we can use AI interpretation of digital images." — Warren Stone (COO)